Medicine & pharma · Pipeline & development
Novo presents preclinical and human data suggesting a role for amylin and calcitonin receptor activation in preserving bone during weight loss at ObesityWeek®
Novo's investigational CagriSema and cagrilintide reduced bone loss in a preclinical model of menopause¹ In small studies conducted in humans, the dual amylin and calcitonin receptor agonists, cagrilintide and zenagamtide, but not the selective amylin receptor agonist NN1213, were...
Original source
Read the source — prnewswire.com ↗We link to the original publisher. The summary above is a short guide; read the original for the full details.